Takeda Ventures

Takeda Ventures, Inc. (TVI) is the corporate venture capital group of Takeda Pharmaceutical Company Limited, Japan's largest pharmaceutical company, founded in 2001 with the vision of generating disruptive technologies and therapeutic solutions for patients through venture-based investments. Operating under Takeda's Center for External Innovation, the firm specifically backs early-stage, preclinical opportunities and platform-based therapeutic companies around the world whose products complement Takeda's pipeline. Its investments are aligned with Takeda's core R&D pillars: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastrointestinal and Inflammation. As a strategic co-investor, TVI partners with academic innovators, entrepreneurs and venture investors, offering portfolio companies access to the deep therapeutic-area expertise, translational capabilities and resources of a multinational pharmaceutical company. Across its history the firm has made well over a hundred investments, producing 8 IPOs and 15 acquisitions, with notable exits including HOOKIPA Pharma, Avidity Biosciences and BiomX, and recent portfolio additions such as Accipiter Biosciences, Integra Therapeutics and Degron Therapeutics. The group remained highly active through 2024 and 2025, completing fresh oncology and biotech rounds. Takeda Ventures is led by President and CEO Graeme R. Matin and a team of roughly eleven, with primary investment activity across the United States, Western Europe and Canada. A separate sister unit, Takeda Digital Ventures, founded in 2018, focuses on digital health. By pairing capital with Takeda's translational and therapeutic expertise, TVI backs the preclinical and platform companies most relevant to its parent's pipeline.